- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01019551
Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients (ERAMUNE-01)
International, Multicenter, Randomized, Non-comparative Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The overall strategy of the ERAMUNE 01 Trial is to treat selected patients with an optimal synergistic antiretroviral regimen plus one or more immunomodulating agents. Among immunomodulating treatments the candidates include therapies from two functional classes: 1) agents that target actively replicating cells and 2) agents activating latently infected cells31.
The novelty of this approach is three-fold: first, the use of highly potent antiretroviral therapy combining drugs with different HIV enzymes targets or receptors and different penetrations in cells, with the aim to suppress virus to truly undetectable levels as measured by the most sophisticated viral quantification techniques; secondly, the addition of an immunomodulatory therapy that specifically targets viral reservoirs to this intensification strategy; and lastly, the rigorous selection of patients having already a low HIV reservoir as measured by peripheral blood HIV DNA content. To our knowledge, this type of strategy has not been implemented. We believe this strategy is feasible.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Badalona, Espagne, 08916
- Fundacio Irsicaixa
-
Barcelona, Espagne, 08036
- University Hospital Clinic of Barcelona
-
-
-
-
-
Paris, France, 75013
- Groupe Hospitalier Pitie-Salpetriere
-
-
-
-
-
Milan, Italie, 20127
- San Raffaele Scientific Institute
-
-
-
-
-
London, Royaume-Uni, NW3 2QG
- Royal Free Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- HIV-1 infection, documented by any licensed ELISA test kit and confirmed by Western Blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test
- 18 ≤ Age ≤ 70 years
- At least 3 years of suppressive ART without any interruption (less than one month cumulative),
- ART treatment unchanged in the 3 months prior to screening
- One HIV plasma viral load (RNA) documented at least 3 years prior to entry, and at least 2 HIV plasma viral loads (RNA) documented per year thereafter
- HIV plasma viral load (RNA) ≤ 500 copies/ml at least 3 years prior to entry and HIV plasma viral load ≤ 500 copies/ml for ≥ 90% of the measures thereafter
- HIV plasma viral load (RNA) below the limit of detection for all values within the past year. Note: the assay used must have a lower limit of detection of 75 copies/ml or less
- CD4+ count ≥ 350 cells/mm3 within 60 days of entry
- 10 ≤ Proviral DNA ≤ 1000 copies/106 PBMCs within 60 days of entry
- Documented laboratory values: Haemoglobin ≥ 10 g/dl, Platelets ≥ 100,000 per microliter, Hepatic transaminases ≤ 2.5 x ULN, Creatinine clearance ≥ 50 ml/min by the Cockcroft-Gault equation
- All subjects must agree not to participate in the conception process (e.g. active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, the subject/partner must use at least two reliable forms of contraceptives (condoms, with or without spermicidal agent, a diaphragm or cervical cap with spermicide, an IUD, or hormone-based contraception), while receiving study treatment and for 6 weeks after stopping study treatment
- Ability and willingness to provide informed consent.
Exclusion Criteria:
- Sexually active men and women who will not practice at least one form of barrier birth control (male partner using condoms, female partner using condoms, other barrier contraception, etc)
- Pregnancy as documented by a urine pregnancy test, or lactating women
- Hepatitis B antigen (HBsAg) positive
- Hepatitis C virus (HCV-Ab) positive or HCV RNA detectable
- Previous use of an integrase inhibitor (ie raltegravir) or a CCR5 inhibitor (ie maraviroc, vicriviroc). Use of raltegravir for non-treatment failure indications such as intensification and toxicity switches is allowed, provided that 1) virologic suppression was maintained before, during and after raltegravir treatment and 2) the patient has not received raltegravir treatment in the 6 months prior to study entry.
- Previous immunologic therapeutic intervention (e.g. IL-2, IL-7) within the past year
- Participation in another clinical drug or device trial where the last dose of drug was within the past 30 days or an investigational medical device is currently implanted
- Diagnosis of cancer within the last 5 years (except basal cell cutaneous cancers and cutaneous KS not requiring systemic therapy)
- Co-morbid condition with an expected survival less than 12 months
- History of hypersensitivity to vaccination
- History of autoimmune disease, such as systemic lupus erythematosis (SLE) or Hashimoto's thyroiditis
- Active drug or alcohol use or dependence that, in the opinion of the center investigator, would interfere with adherence to study requirements.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: ARM A : ART intensification alone
Raltegravir PO 400 mg BID Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen
|
Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
|
Expérimental: ARM B : ART intensification + Immunomodulation
Raltegravir PO 400 mg BID during 56 weeks Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen during 56 weeks 3 weekly injections of r-hIL-7 (CYT107) at a 20 micrograms/kg dose starting at Week 8
|
Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Decrease from baseline in HIV proviral DNA in the PBMCs at week 56 of at least 0.5 log, as expressed as numbers of HIV DNA copies per million PBMCs
Délai: End of study
|
End of study
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Percentage of patients with undetectable HIV DNA (< 1 copy/million PBMCs) after 56 weeks
Délai: End of study
|
End of study
|
Change from baseline in HIV proviral DNA in any of the sub-compartments explored (gut lymphoid tissue), as expressed as numbers of HIV DNA copies per million mononuclear cells
Délai: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Change from baseline in HIV proviral DNA in the CD4 T cell subsets, as expressed as numbers of HIV DNA copies per million CD4 T cells
Délai: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Changes from baseline in HIV plasma viral load (number of copies of HIV RNA per millilitre), measured by quantitative ultrasensitive PCR
Délai: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Proportion of patients without inducible HIV RNA, DNA and/or p24
Délai: End of study
|
End of study
|
Changes from baseline in CD4 lymphocyte count
Délai: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Changes in the activation and differentiation markers of the CD4 and CD8 peripheral blood T cells
Délai: End of study
|
End of study
|
Development of a mathematical model exploring the dynamics of the HIV-DNA decay
Délai: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Development of a mathematical model exploring the dynamics of T cells activation (CD38)
Délai: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Genetic determinants influencing HIV-1-specific immune response and HIV control
Délai: End of study
|
End of study
|
Antiretroviral drugs pharmacokinetics in the blood and rectal mucosa
Délai: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Safety and tolerability of the intensified treatment regimen and immunomodulatory therapy
Délai: From Day 0 to Week 56
|
From Day 0 to Week 56
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Christine Katlama, MD, Groupe Hospitalier Pitie-Salpetriere
- Directeur d'études: François LECARDONNEL, MSc, ORVACS
- Chaise d'étude: Steven DEEKS, MD, University of California, San Francisco
Publications et liens utiles
Publications générales
- Murphy RL, Autran B, Katlama C, Brucker G, Debre P, Calvez V, Clotet B, Clumeck N, Costagliola D, Deeks SG, Dorrell L, Gatell J, Haase A, Klein M, Lazzarin A, McMichael AJ, Papagno L, Schacker TW, Wain-Hobson S, Walker BD, Youle M. A step ahead on the HIV collaboratory. Science. 2009 Jun 5;324(5932):1264-5. doi: 10.1126/science.324_1264b. No abstract available.
- Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS. 2011 Apr 24;25(7):885-97. doi: 10.1097/QAD.0b013e3283467041.
- Lafeuillade A. Eliminating the HIV reservoir. Curr HIV/AIDS Rep. 2012 Jun;9(2):121-31. doi: 10.1007/s11904-012-0115-y.
- Cohen J. The emerging race to cure HIV infections. Science. 2011 May 13;332(6031):784-5, 787-9. doi: 10.1126/science.332.6031.784. No abstract available.
- Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N. Finding a cure for HIV: will it ever be achievable? J Int AIDS Soc. 2011 Jan 24;14:4. doi: 10.1186/1758-2652-14-4.
- Katlama C, Lambert-Niclot S, Assoumou L, Papagno L, Lecardonnel F, Zoorob R, Tambussi G, Clotet B, Youle M, Achenbach CJ, Murphy RL, Calvez V, Costagliola D, Autran B; EraMune-01 study team. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. AIDS. 2016 Jan;30(2):221-30. doi: 10.1097/QAD.0000000000000894.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- ORVACS 010
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Infection par le VIH-1
-
Academisch Medisch Centrum - Universiteit van Amsterdam...ComplétéInfection par le VIH-1Pays-Bas
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)Complété
-
Janssen R&D IrelandComplétéInfection par le VIH-1États-Unis, Australie, France, Royaume-Uni, Chine, Belgique, Allemagne, Espagne, Argentine, Roumanie, Afrique du Sud, Canada, Danemark, Pays-Bas, Chili, Porto Rico, L'Autriche, Fédération Russe, Thaïlande, Suède, Taïwan
-
Gilead SciencesComplétéInfection par le VIH-1Espagne, Royaume-Uni, Italie, France, Belgique
-
Bionor Immuno ASCelgene CorporationComplétéInfection par le VIH-1Allemagne
-
Bristol-Myers SquibbRésiliéInfection par le VIH-1Thaïlande, États-Unis, Australie, Canada, Espagne, Colombie, Afrique du Sud, Hongrie, France, Pérou, Argentine, Chili, Mexique
-
AbbVie (prior sponsor, Abbott)ComplétéInfection par le VIH-1
-
Nantes University HospitalComplété
-
Kirby InstituteComplété
-
Merck Sharp & Dohme LLCRésiliéInfection par le VIH-1
Essais cliniques sur ART Intensification
-
Laboratoires NEGMAInconnue
-
Asahi Kasei Pharma CorporationComplétéCancer du côlon postopératoire de stade II/IIIJapon
-
Hampton VA Medical CenterRésiliéTrouble de stress post-traumatique | Trouble de stress, post-traumatiqueÉtats-Unis
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ComplétéCancer de la tête et du cou | Cancer de l'oropharynxÉtats-Unis
-
Centre Francois BaclesseLigue contre le cancer, FranceComplété
-
University Hospital, GrenobleUniversité Grenoble-AlpesRecrutementAnxiété dépression | Régulation des émotionsFrance
-
University of Nove de JulhoComplétéHypominéralisation des incisives molairesBrésil
-
University of New MexicoComplétéFormation sur simulateur d'anesthésie régionale guidée par ultrasonsÉtats-Unis
-
Busra Nur TemurPas encore de recrutementAnxiété | Transplantation ; Échec, Rein | Complication de greffe
-
Memorial Sloan Kettering Cancer CenterComplétéCancer de la tête et du cou | Cancer du nasopharynx | Cancer de l'oropharynx | Cancer de la cavité buccale | Cancer du larynx | Cancer des sinus paranasaux | Cancer de l'hypopharynxÉtats-Unis